Tips for Process Robustness at Scale

In the context of a recent scale-up for a sterile injectable product, operators noticed an increase in out-of-specification (OOS) results during potency testing. Manufacturing batch reports indicated variability in purity…

During a recent biopharmaceutical scale-up, operators observed several warning signs that prompted immediate investigation. Critical parameters related to yield and product quality were trending out of specification. Initially, the symptoms…

Recognizing early warning signs of process instability is critical in the high potency manufacturing environment. Common symptoms that might suggest a lack of process robustness include:Click to read the full…

The first step in addressing process robustness challenges is recognizing the symptoms or signals that indicate potential issues. Symptoms can vary but often include:Click to read the full article.

Identifying early warning signs is crucial for mitigating risks associated with mixing robustness during the scale-up phase. Common symptoms that might indicate issues with the mixing process include:Click to read…

Identifying symptoms of inadequate mixing robustness involves careful observation and quality monitoring. Common indicators include:Click to read the full article.

Identifying symptoms of drying inefficiencies early allows for timely corrective measures. Common signals include:Click to read the full article.

Identifying the early signs of inadequate drying robustness is crucial for timely interventions. Common symptoms may include:Click to read the full article.

Identifying the symptoms associated with compromised dissolution robustness is the first step in addressing potential issues in pharmaceutical manufacturing. Some common symptoms that may signal problems include:Click to read the…

Evaluation Strategies for Dissolution Robustness Post Process Scale-Up In pharmaceutical manufacturing, the transition from bench to commercial scale often poses challenges that could impact the final product quality significantly. One…

During the transition to larger bioreactors, operators began observing several troubling trends:Click to read the full article.

During the recent scale-up of a monoclonal antibody (mAb) production process, several symptoms emerged that indicated potential process instability. Operators reported unusual fluctuations in process parameters, specifically during the purification…